CTOs on the Move

Specific Diagnostics

www.specific.com

 
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Intrapace

Intrapace is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kelcourt Plastics Inc

Kelcourt Plastics Inc is a San Clemente, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aesculap

Aesculap is a Center Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avedro

Avedro is a privately held pharmaceutical and medical device company advancing the science and technology of corneal cross-linking and refractive correction.

Shockwave Medical

Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotrispy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. In peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, IVL demonstrated safety and consistent procedure success with low procedural complications. The technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatments. And because it is built on a traditional balloon catheter platform, it integrates seamlessly with clinicians` existing workflow.